DHS-NALOXONE KIT PILOT PROGRAM House SponsorsRep. Lindsey LaPointe-Maurice A. West, II-Natalie A. Manley-Ann M. Williams, Kelly M. Cassidy, Bob Morgan, Aarón M. Ortíz, Gregg Johnson and Michelle Mussman 1/7/2025HouseSession Sine Die 305 ILCS 65/15 new Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.House Committee Amendment No. 1 In a provision requiring the Department of Human Services to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency service providers and bystanders during the 2-year pilot program, provides that the data must (i) include the number of individuals who survived as a result of the 8-milligram naloxone nasal spray intervention and those who became deceased and (ii) include the number of opioid overdose reversals attributed to the administration of the 8-milligram naloxone nasal spray intervention, by county (rather that requiring that the data collected must also include the number of individuals who survived an opioid overdose after receiving the 8-milligram naloxone nasal spray and the number of individuals who died of an opioid overdose after receiving the 8-milligram naloxone nasal spray). 2/10/2023HouseFiled with the Clerk by Rep. Lindsey LaPointe 2/14/2023HouseFirst Reading 2/14/2023HouseReferred to Rules Committee 2/28/2023HouseAssigned to Mental Health & Addiction Committee 3/6/2023HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Lindsey LaPointe 3/6/2023HouseHouse Committee Amendment No. 1 Referred to Rules Committee 3/6/2023HouseAdded Chief Co-Sponsor Rep. Maurice A. West, II 3/7/2023HouseHouse Committee Amendment No. 1 Rules Refers to Mental Health & Addiction Committee 3/7/2023HouseAdded Chief Co-Sponsor Rep. Natalie A. Manley 3/7/2023HouseAdded Chief Co-Sponsor Rep. Ann M. Williams 3/7/2023HouseAdded Co-Sponsor Rep. Kelly M. Cassidy 3/7/2023HouseAdded Co-Sponsor Rep. Bob Morgan 3/7/2023HouseAdded Co-Sponsor Rep. Aarón M. Ortíz 3/9/2023HouseHouse Committee Amendment No. 1 Adopted in Mental Health & Addiction Committee; by Voice Vote 3/9/2023HouseDo Pass as Amended / Short Debate Mental Health & Addiction Committee; 020-000-000 3/9/2023HousePlaced on Calendar 2nd Reading - Short Debate 3/13/2023HouseAdded Co-Sponsor Rep. Gregg Johnson 3/22/2023HouseSecond Reading - Short Debate 3/22/2023HouseHeld on Calendar Order of Second Reading - Short Debate 3/27/2023HouseRule 19(a) / Re-referred to Rules Committee 4/6/2023HouseAdded Co-Sponsor Rep. Michelle Mussman 1/7/2025HouseSession Sine Die